News

A cancer marker called NEDD9 is a critical mediator of pulmonary arterial hypertension (PAH) and could be a therapeutic target, according to new research. The study, “NEDD9 targets COL3A1 to promote endothelial fibrosis and pulmonary arterial hypertension,” was published in the journal Science Translational Medicine. Fibrosis…

Scleroderma patients diagnosed with pulmonary arterial hypertension (PAH) are at a high risk of PAH-related death, especially in the four years after the PAH diagnosis, a study shows. Also, being a man, having diffuse scleroderma, and worse scores on respiratory- and heart-related tests were associated with a higher risk of…

Five Canadian provinces, Alberta, Ontario, Saskatchewan, Manitoba, and Newfoundland and Labrador, have approved public health insurance coverage for Uptravi (selexipag), a pulmonary arterial hypertension (PAH) therapy developed by Actelion. Quebec was the first province to approve public funding for Uptravi in Canada, in March 2018. The…

Intravenous infusions of treprostinil can improve disease severity in children with pulmonary hypertension (PH) associated with congenital diaphragmatic hernia (CDH), a birth defect that occurs when the diaphragm does not form properly, a new study shows. However, these babies have a greater likelihood of needing extracorporeal respiratory support,…

A Phase 1 clinical trial (NCT03464864) found that treprostinil can be safely delivered at varying doses using Technosphere, a novel inhalation device, MannKind, the device’s developer, announced. Treprostinil — a vasodilator —  was approved by the U.S. Food and Drug Administration (FDA) in 2002 for the treatment of pulmonary…

Denovo Biopharma recently entered an exclusive global license agreement with Stanford University School of Medicine to further develop and market its lead compound, DB102 (formerly called enzastaurin), as a potential treatment for pulmonary arterial hypertension (PAH) and emphysema. In research in preclinical models at Stanford, DB102 was found…

Canada’s healthcare system is excellent for people with common ailments like diabetes or high blood pressure, but it’s “basically failing the nearly three million Canadians with rare diseases.” So says Durhane Wong-Rieger, president and CEO of the Canadian Organization for Rare Disorders (CORD), a Toronto-based network representing 102 patient advocacy…

A molecular mechanism involving the tight balance between two proteins — Gal-1 and CaV1.2 — was found to regulate the behavior of blood vessel cells, directly contributing to hypertension. This finding provides new insights into the underlying processes that trigger arterial contraction and hypertension, and its researchers suggest that a…

As President Trump signed the recently passed Right to Try legislation into law in a White House ceremony, Jordan McLinn of Indianapolis tried twice to embrace him. The third time, 9-year-old Jordan finally got the hug he wanted — as well as a kiss on the forehead. The video of…

A new Phase 2 study evaluating Tenax Therapeutic’s investigational levosimendan as a therapy for pulmonary hypertension (PH) associated with heart failure and preserved left ventricular ejection fraction (PH-HFpEF) — a type of PH related to left heart disease – will soon begin recruiting participants, the company announced. Patients…

Chronic thromboembolic pulmonary hypertension (CTEPH) may be an inherited genetic disease, a new study suggests. The results were recently presented at the American Thoracic Society (ATS) 2018 annual conference May 18-23 in San Diego. CTEPH, a rare form of pulmonary hypertension, is caused by blood clots that travel to the…

Should scientists have the right to edit the genes of future generations to eliminate hundreds, if not thousands, of potential rare diseases? Or should researchers restrict their use of genome editing to somatic cells, so that they don’t pass changes on to the next generation? What about stem-cell research, three-parent…